Antiviral Res 2000 Sep 1;47(3):215-220
In vitro activity of pleconaril and AG7088 against selected serotypes and
clinical isolates of human rhinoviruses.
Kaiser L, Crump CE, Hayden FG
Department of Medicine, Division of Epidemiology and Virology, University of Virginia School of
Medicine, Box 473, 22908, Charlottesville, VA, USA
[Record supplied by publisher]
Background: We tested the in vitro activity of pleconaril and AG7088 against five numbered
human rhinovirus (HRV) serotypes and 46 clinical HRV isolates of undefined serotype recovered
from patients with common colds. Antiviral effect of pleconaril and AG7088 were assessed by
cytophathic effect (CPE) inhibition assays in Ohio HeLaI cells using microscopic and
spectrophotometric methods. Both compounds were tested at concentrations of 1.0, 0.1 and
0.01 mug/ml. For the numbered HRV serotypes, the median EC(50) value determined by the
microscopic CPE inhibition was slightly better for AG7088 compared to pleconaril (P=0.02) but
was similar by spectrophotometric assay (P=0.15). For clinical HRV isolates the median EC(50)
value determined microscopically was 0.01 mug/ml range, <0.01-0.04 mug/ml) for AG7088
compared to 0.07 mug/ml (range, <0.01->1 mug/ml) for pleconaril (P<0.001). The median
EC(50) value determined by spectrophotometric assay was 0.01 mug/ml (range, <0.01-0.04
mug/ml) for AG7088 compared to 0.04 mug/ml (range, <0.01->1 mug/ml) for pleconaril
(P<0.001). By either the microscopic or spectrophotometric methods the median EC(50) value
of AG7088 was <1.0 mug/ml for all isolates and was >10.0 mug/ml of pleconaril for
approximately 9% of isolates. In vitro AG7088 appeared to be more potent and to have a
broader antirhinoviral spectrum than pleconaril among clinical HRV isolates. The clinical
relevance of these in vitro results needs to be determined in controlled clinical trials. |
